2D DIGE of the cerebrospinal fluid proteome in neurological diseases (Q37685107)

22 August 2017

1 reference

title

2D DIGE of the cerebrospinal fluid proteome in neurological diseases (English)

1 reference

22 August 2017

0 references

1

Hayrettin Tumani

1 reference

22 August 2017

2

Vera Lehmensiek

1 reference

22 August 2017

3

Stefan Lehnert

1 reference

22 August 2017

4

Markus Otto

1 reference

22 August 2017

author name string

Johannes Brettschneider

series ordinal

5

1 reference

22 August 2017

publication date

1 February 2010

1 reference

Expert Review of Proteomics

22 August 2017

published in

1 reference

22 August 2017

volume

7

1 reference

22 August 2017

issue

1

1 reference

22 August 2017

page(s)

29-38

1 reference

Biomarkers and surrogate endpoints: preferred definitions and conceptual framework

22 August 2017

cites work

1 reference

Development of biomarkers in multiple sclerosis

21 January 2018

1 reference

Surrogate endpoints in clinical trials: definition and operational criteria

21 January 2018

1 reference

Cerebrospinal fluid biomarkers of neurodegeneration in chronic neurological diseases

21 January 2018

1 reference

Flow rate of cerebrospinal fluid (CSF)--a concept common to normal blood-CSF barrier function and to dysfunction in neurological diseases

21 January 2018

1 reference

Proteome analysis of cerebrospinal fluid in Guillain-Barré syndrome (GBS)

21 January 2018

1 reference

Cerebrospinal fluid proteome profile in multiple sclerosis

21 January 2018

1 reference

Proteomics for protein expression profiling in neuroscience

21 January 2018

1 reference

The development of the DIGE system: 2D fluorescence difference gel analysis technology

21 January 2018

1 reference

Difference gel electrophoresis: a single gel method for detecting changes in protein extracts

21 January 2018

1 reference

Proteome studies of CSF in AD patients.

21 January 2018

1 reference

Comparative proteomic analysis of intra- and interindividual variation in human cerebrospinal fluid

21 January 2018

1 reference

Independent protein-profiling studies show a decrease in apolipoprotein A1 levels in schizophrenia CSF, brain and peripheral tissues

21 January 2018

1 reference

CSF metabolic and proteomic profiles in patients prodromal for psychosis

21 January 2018

1 reference

Erythropoietin in cerebrospinal fluid: age-related reference values and relevance in neurological disease

21 January 2018

1 reference

Proteomics analysis of human cerebrospinal fluid

21 January 2018

1 reference

Identification of proteins in human cerebrospinal fluid using liquid-phase isoelectric focusing as a prefractionation step followed by two-dimensional gel electrophoresis and matrix-assisted laser desorption/ionisation mass spectrometry

21 January 2018

1 reference

Proteomics analysis of prefractionated human lumbar cerebrospinal fluid

21 January 2018

1 reference

All about DIGE: quantification technology for differential-display 2D-gel proteomics

21 January 2018

1 reference

Cerebrospinal fluid-optimized two-dimensional difference gel electrophoresis (2-D DIGE) facilitates the differential diagnosis of Creutzfeldt-Jakob disease

21 January 2018

1 reference

Evaluation of two-dimensional differential gel electrophoresis for proteomic expression analysis of a model breast cancer cell system

21 January 2018

1 reference

The synergy of elemental and biomolecular mass spectrometry: new analytical strategies in life sciences

21 January 2018

1 reference

The ABC's (and XYZ's) of peptide sequencing

21 January 2018

1 reference

The application of proteomic techniques to fungal protein identification and quantification

21 January 2018

1 reference

Utility of mass spectrometry for proteome analysis: part I. Conceptual and experimental approaches

21 January 2018

1 reference

Utility of mass spectrometry for proteome analysis: part II. Ion-activation methods, statistics, bioinformatics and annotation

21 January 2018

1 reference

A panel of cerebrospinal fluid potential biomarkers for the diagnosis of Alzheimer's disease.

21 January 2018

1 reference

Cerebrospinal fluid tau protein as a biochemical marker for Alzheimer's disease: a community based follow up study

21 January 2018

1 reference

Classification and prediction of clinical Alzheimer's diagnosis based on plasma signaling proteins

21 January 2018

1 reference

Isolated blood-cerebrospinal fluid barrier dysfunction: prevalence and associated diseases.

21 January 2018

1 reference

The STARD statement for reporting studies of diagnostic accuracy: explanation and elaboration

21 January 2018

1 reference

Minimum information about a microarray experiment (MIAME)-toward standards for microarray data

21 January 2018

1 reference

REporting recommendations for tumour MARKer prognostic studies (REMARK)

21 January 2018

1 reference

Guidelines for the next 10 years of proteomics

21 January 2018

1 reference

The minimum information about a proteomics experiment (MIAPE)

21 January 2018

1 reference

A gel-based proteomic comparison of human cerebrospinal fluid between inflicted and non-inflicted pediatric traumatic brain injury

21 January 2018

1 reference

Proteomic identification of potential protein markers in cerebrospinal fluid of GBS patients

21 January 2018

1 reference

Alteration of DBP levels in CSF of patients with MS by proteomics analysis

21 January 2018

1 reference

Quantitative proteomic analysis of the cerebrospinal fluid of patients with multiple sclerosis

21 January 2018

1 reference

Protein transfer at the blood cerebrospinal fluid barrier and the quantitation of the humoral immune response within the central nervous system.

21 January 2018

1 reference

Cerebrospinal fluid analysis: disease-related data patterns and evaluation programs

21 January 2018

1 reference

Cerebrospinal Fluid Proteomic Profiling of HIV-1-Infected Patients with Cognitive Impairment

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1586/EPR.09.99

1 reference

22 August 2017

1 reference